Haleon PLC, globally known for transforming oral health research, has been committing to various financial strategies involving extensive share buyback programs to optimize its capital structure and potentially enhance shareholder value. The company has been executing these programs with significant share purchase, adjusting its total voting rights and share capital.
Kepler Capital,
Berenberg Bank, and
Barclays have maintained their
Buy rating for Haleon, showing confidence in the company's standing.
Pfizer has sold all of its Haleon stakes amounting to around $3.24 billion, marking their exit in the consumer healthcare giant. Haleon's shares have seen some volatility, notably including a downward gap to $11.01. Despite the risks, the company continues with a stable performance according to
Morgan Stanley and remains focused on its 2025 growth target. Meanwhile, insiders, including executives, have held onto shares, reflecting trust in the company's long-term potential. Haleon remains enthused about their projected revenue growth for 2025, banking on strategic expansion, steady organic growth, and robust innovation.
Haleon Stocks News Analytics from Tue, 01 Oct 2024 07:00:00 GMT to Fri, 04 Jul 2025 18:10:00 GMT -
Rating 2
- Innovation 0
- Information 8
- Rumor -4
